Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
On August 27, 2026, the U.S. District Court for the District of New Jersey preliminarily approved a class-action settlement concerning alleged unsolicited fax communications. The settlement involves Indegene's wholly-owned subsidiary, Indegene, Inc. A maximum fund of approximately USD 4.72 million has been established, with potential payments of USD 250 per eligible claim. The actual financial impact depends on the number of valid claims submitted by the December 9, 2026 deadline. A final court approval hearing is scheduled for January 12, 2027. No payments have been made as of August 31, 2026.
Indegene Limited has scheduled meetings with institutional investors. On September 11, 2026, a one-to-one meeting was planned with Premji Invest in Bangalore to provide business updates. The company also has other scheduled analyst or institutional investor meetings and conference calls.
As of September 18, 2026, Indegene's stock closed at ₹600.1. The stock has shown positive returns over various periods, including a 6-month return of 33% and a Year-to-Date (YTD) return of 15%. Technically, the daily trend shows a bullish Supertrend indicator at ₹554.6, with the closing price above both the 20-day and 50-day Exponential Moving Averages (EMAs). However, the monthly trend indicates a bearish Supertrend at ₹661.9, suggesting a mixed technical picture across different timeframes.
As of 18 Sept 2026, 03:30 pm
Showing 3 of 14 candles
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Primary driver: Price swings are higher than typical
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹1,063.10 crore | ₹1,003.40 crore | ₹942.10 crore | ₹804.20 crore | ₹760.80 crore |
| Profit Before Exceptional Items And Tax | PEAK₹152.70 crore | ₹125.40 crore | ₹134.70 crore | ₹133.10 crore | ₹152.10 crore |
| Profit Before Tax | PEAK₹152.70 crore | ₹105.10 crore | ₹134.70 crore | ₹133.10 crore | ₹152.10 crore |
| Other Expenses | PEAK₹229.80 crore | ₹207.40 crore | ₹214.60 crore | ₹147.80 crore | ₹124 crore |
| Finance Costs | ₹6.40 crore | PEAK₹7.20 crore | ₹4.60 crore | ₹3.80 crore | ₹3.70 crore |
| Other Unallocable Expenditure Net Off Un Allocable Income | ₹20.70 crore | PEAK₹59.90 crore | ₹36.30 crore | ₹12.90 crore | ₹6.70 crore |
Revenue from operations reached ₹1,063.10 crore in the quarter. This was 5.95% higher than the previous quarter (₹1,003.40 crore) and 39.73% higher than the year-ago quarter (₹760.80 crore). The sequential growth rate was similar to the 6.5% pace recorded in the preceding quarter.
Revenue grew nearly 40% year-over-year, but profit before tax was essentially flat as other expenses, finance costs, and unallocable expenditure surged. Sequentially, profit recovered strongly, aided by the absence of the prior quarter’s exceptional charge and a reduction in unallocable costs. The year-over-year profit stagnation highlights a quarter in which cost increases outpaced revenue growth.
Exchange disclosures and regulatory announcements for Indegene.
Indegene Limited scheduled an in-person one-to-one meeting with Premji Invest, represented by Partner Ajitesh Nair, to be held on September 11, 2026, at 10:00 AM in Bangalore. The meeting's agenda is focused on providing business updates to the institutional investor. Contact for the event is Abhishek Agarwal via ir@indegene.com or 8046744567.
On August 27, 2026, the U.S. District Court for the District of New Jersey issued an order preliminarily approving a class-action settlement involving Indegene Limited's wholly-owned subsidiary, Indegene, Inc., regarding litigation under the Telephone Consumer Protection Act. The settlement framework establishes a maximum fund of approximately USD 4.72 million with payments of USD 250 per eligible claim, subject to a claims-made structure where unclaimed amounts revert to defendants. While the court appointed Analytics as the Settlement Administrator and scheduled a final approval hearing for January 12, 2027, no payments have been made yet, and the actual financial impact remains contingent on the number of valid claims received by the December 9, 2026 deadline.
On August 27, 2026, the U.S. District Court for the District of New Jersey preliminarily approved a proposed class action settlement regarding alleged unsolicited fax communications under the Telephone Consumer Protection Act. The class includes approximately 18,851 unique fax numbers. Notice to class members must be issued by September 10, 2026, with claims, exclusions, and objections due by December 9, 2026, and a final approval hearing set for January 12, 2027. The settlement remains subject to final court approval.
On August 19, 2026, Indegene Limited authorized the execution of a definitive settlement agreement regarding the class-action lawsuit Progressive Health and Rehab Corp. v. Indegene, Inc., pending in the U.S. District Court for the District of New Jersey. The settlement framework establishes a maximum potential fund of approximately USD 4.72 million based on claims of USD 250 per eligible fax transmission out of a certified class of roughly 18,851 unique numbers, though actual payments will depend on valid claims submitted under a reversionary structure requiring no upfront funding. The agreement remains subject to final execution by parties and approval by the U.S. District Court, with administration costs estimated at USD 42,559.
Indegene, Inc., a subsidiary of Indegene Limited, has finalized a settlement agreement for a U.S. class action lawsuit filed on July 17, 2025, in the U.S. District Court, District of New Jersey, alleging violations of the Telephone Consumer Protection Act over unsolicited faxes. The settlement framework provides for a maximum fund of approximately USD 4.72 million (USD 250 per eligible claim) on a claims-made and reversionary basis, meaning actual payout depends on valid claims and the defendants are not required to pre-fund the full amount. The settlement administrator is Analytics, with an estimated cost of USD 42,559, and the next steps include execution, court filing, and approval.
INDEGENE LIMITED has informed the Exchange about Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B) |SUBJECT: Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B)
Indegene Limited scheduled investor/analyst meetings on August 24, 2026, in Bengaluru, with MFS International Singapore, ASK Investment Managers, and Mirae Mutual Fund; and on August 25, 2026, in Bengaluru with Goldman Sachs Asset Management and Seven Canyon Advisors. All meetings will be in-person.
Recent market and company developments associated with Indegene.
Kotak, Infosys, TCS, TechM, Coforge, Hexaware, Indegene
Market expert Raja Venkatraman shares his top stock picks for 19 August. Here’s his technical outlook and trade strategy.
Sensex Today | Stock Market LIVE Updates: Sensex contracts face weekly expiry, testing the CAS system. Nifty defended 24,500, Nifty Bank defended 57,500. Over 50 major results are due today.
Indegene, Motilal Oswal, Recommendations, Neutral
Indegene, Indegene stocks, Indegene shares, Nomura, Indegene Q1 results
Q1 Results LIVE Updates: Four Nifty companies, ITC, Maruti Suzuki, Sun Pharma and Bajaj Finserv report results today to round off this week dominated by earnings. Broader market names like Dixon Tech, Indian Oil, Glenmark Pharma, GMDC, ABB India, SJVN, GAIL and NALCO among many others will also be reporting their results. The big result reactions of the day include the likes of Swiggy, Mazagon Dock, Thermax, Bajaj Finance's earnings call and upgrades among others.
Sensex Today | Stock Market Live Updates: We are the last half the week's trade, and the Indian markets are trading on a cautious note. The Nifty is looking to close the week in green, and is trading around 24,300. The Nifty Bank is trying to hold it together, now up around 100 points, moving around 57,250. TCS, Infosys and Wipro are the top laggards.
Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Bajaj Finance, Swiggy, Tata Steel, Mazagon Dock Shipbuilders, Torrent Pharmaceuticals, LIC Housing Finance, AWL Agri Business, RailTel Corporation of India, Aarti Industries, Indegene, Global Health, Chambal Fertilisers & Chemicals, Thermax, Data Patterns (India), Rainbow Children's Medicare, Satin Creditcare Network, GNG Electronics, MOIL, Nucleus Software Exports
Comprehensive Section Breakdown for Indegene
Strategic Vision: Digital commercialization services for life sciences industry.
• Proprietary digital platforms
• Machine learning tools
• Automated content generation systems
Indegene Limited reported a 39.7% rise in revenue for the quarter ended 30 June 2026 compared with the same period last year. However, profit before tax was nearly unchanged, as sharp increases in other expenses, finance costs, and unallocable expenditure absorbed the revenue gains. Sequentially, profit rebounded from the previous quarter, helped by the absence of a one-time exceptional charge and lower unallocable costs.
Profit before tax (PBT) was ₹152.70 crore. This represents a 45.3% increase from the previous quarter’s ₹105.10 crore, but only a 0.4% rise from ₹152.10 crore in the same quarter last year.
The large sequential improvement partly reflects the absence of an exceptional item that weighed on the prior quarter. In Q4 of the previous fiscal year, an exceptional charge of ₹20.30 crore reduced reported PBT to ₹105.10 crore. Excluding that charge, underlying PBT in the prior quarter was ₹125.40 crore. On that underlying basis, PBT still grew 21.8% sequentially, outpacing the 5.95% revenue growth.
Year-over-year, however, PBT was virtually flat despite the ₹302.30 crore increase in revenue.
The year-over-year profit stagnation coincided with significant increases in several expense lines.
Together, these three items increased by ₹122.50 crore, absorbing a large portion of the ₹302.30 crore revenue gain. Employee benefit expense, the largest cost component, was ₹659.10 crore, representing 62.0% of revenue. The combination of these cost movements left pre-tax profit nearly unchanged from the prior year.
Tax expense for the quarter was ₹36.50 crore, resulting in an effective tax rate of 23.9% on the ₹152.70 crore pre-tax profit. This compares with a tax expense of ₹35.70 crore in the year-ago quarter.
Net profit was ₹116.20 crore, up 45.8% from the previous quarter (₹79.70 crore) but down 0.2% from ₹116.40 crore a year earlier.
Comprehensive income was ₹128.00 crore, a 5.0% decline from the previous quarter’s ₹134.70 crore. The drop occurred despite higher net profit, as other comprehensive income fell sharply to ₹11.80 crore from ₹55.00 crore in the prior quarter.
Category: B2B Services
Assists life sciences companies in designing and executing omni-channel marketing campaigns, content management, and digital customer interactions.
Category: B2B Services
Supports medical writing, regulatory submissions, safety monitoring, and scientific communications.
Category: B2B Services
Provides clinical data management, trial operations assistance, and analytics frameworks to optimize drug development lifecycles.
Core Thesis: Indegene leverages a global delivery model combining expertise with digital platforms and automation to serve multinational life sciences companies.
• Global Delivery Model: Operates under a global delivery model to provide services to multinational life sciences companies. • Digital Platforms and Tools: Combines proprietary digital platforms, machine learning tools, and automated content generation systems. • Subject Matter Expertise: Integrates clinical subject matter expertise with digital capabilities.